7. PRO FORMA FINANCIAL INFORMATION (UNAUDITED)

3 Months Ended

Dec. 31, 2019

Pro Forma Financial Information

PRO FORMA FINANCIAL INFORMATION (UNAUDITED)

The following unaudited pro-forma data summarizes the results of operations for the three months ended December 31, 2019 and 2018, as if the Mergers with Cure Based Development had been completed on October 1, 2017. The pro-forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the Mergers had taken place on October 1, 2017. The pro-forma financial information represents the continuing operations only.

	Three Months Ended December 31, 2019		Three Months Ended December 31, 2018
Net sales	$	N/A*	$	3,549,115
Operating income (loss)	$	N/A*	$	(828,744	)
Net income (loss)	$	N/A*	$	(2,180,308	)
Net income per share – average weighted shares	$	N/A*	$	(0.09	)
Net income per share – fully diluted	$	N/A*	$	-

* All entities were consolidated effective December 21, 2018 therefore, the results of operations are included in these condensed financial statements.

For the per share calculation prior to April 2019, it is being assumed that the shares to be issued contractually under the Merger Agreement, upon shareholder approval, were issued at the beginning of each period. This would account for an additional 6,500,000 shares issued directly to the members of Cure Based Development and another 8,750,000 shares issued which would have a voting proxy and leak out on voting rights over a 5 year period.